SVRA — Savara Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1160308 ·
Last close
$4.83
Market Cap
$992.37M
52W High
$7.01
52W Low
$3.35
ADV30
2,009,269
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -40,965,000 | -40,228,000 | 192,138,000 | 41,800,000 | 48,478,000 |
| Mar 2026 | 0 | — | -38,137,000 | -37,284,000 | 221,645,000 | 38,791,000 | 45,606,000 |
| Dec 2025 | 0 | — | -33,419,000 | -32,236,000 | 253,436,000 | 33,180,000 | 50,303,000 |
| Sep 2025 | 0 | — | -30,255,000 | -29,561,000 | 140,924,000 | 16,277,000 | 46,538,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-106,894,000
Investing CF
$-8,991,000
Financing CF
$135,293,000
CapEx
$-73,000
Dividends Paid
—
Buybacks
$-5,165,000
EPS Diluted TTM
$-0.55
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-645,371,000
Inventory
—
Receivables
$1,053,000
ST Investments
$163,981,000
EBIT TTM
$-133,251,000
Pretax Income TTM
$-129,482,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,763,000 | -118,837,000 | 253,436,000 | 50,303,000 | 203,133,000 | -101,037,000 |
| Dec 2024 | 0 | -102,399,000 | -95,881,000 | 212,879,000 | 41,430,000 | 171,449,000 | -89,088,000 |
| Dec 2023 | 0 | -59,210,000 | -54,698,000 | 177,564,000 | 37,192,000 | 140,372,000 | -51,061,000 |
| Dec 2022 | 0 | -38,043,000 | -38,150,000 | 139,777,000 | 31,999,000 | 107,778,000 | -34,554,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-129,482,000
OpCashFlow TTM
—
Assets (Latest)
$221,645,000
Forward EPS
$-0.31
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $4.87 · call oi: 10,217 · put oi: 319
Expected Move to 2026-10-16:
±$0.54
(11.09%) —
implied range
$4.33 –
$5.41
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTGO | Latigo Biotherapeutics, Inc. | $980.57M | $14.79 | — |
| OPK | OPKO HEALTH, INC. | $1.02B | $1.37 | — |
| SPTX | Seaport Therapeutics, Inc. | $958.73M | $17.91 | — |
| AKTS | Aktis Oncology, Inc. | $953.47M | $17.74 | — |
| ANRO | Alto Neuroscience, Inc. | $942.99M | $24.03 | — |
News headlines (Yahoo Finance, 1h cache)
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
2026-08-24 20:05 · Yahoo
Savara Announces New Employment Inducement Grant
2026-08-20 20:05 · Yahoo
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
2026-07-30 12:05 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
2026-06-27 15:34 · Yahoo
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
2026-06-08 17:13 · Yahoo
Savara Inc. (SVRA) Reports Q1 Financial Results
2026-05-22 18:43 · Yahoo
What Insmed Stock's Premium Is Actually Buying
2026-08-07 15:39 · Yahoo
Savara Announces Chief Financial and Administrative Officer Transition
2026-06-08 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.